These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 17146111)
1. Collimator selection, acquisition speed, and visual assessment of 131I-tositumomab biodistribution in a phantom model. Tan HK; Wassenaar RW; Zeng W J Nucl Med Technol; 2006 Dec; 34(4):224-7. PubMed ID: 17146111 [TBL] [Abstract][Full Text] [Related]
2. Comparison of medium- and high-energy collimators for 131I-tositumomab dosimetry. Mah E; Spicer KM J Nucl Med Technol; 2007 Sep; 35(3):148-53. PubMed ID: 17823454 [TBL] [Abstract][Full Text] [Related]
5. Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Antonescu C; Bischof Delaloye A; Kosinski M; Monnin P; Schaffland AO; Ketterer N; Grannavel C; Kovacsovics T; Verdun FR; Buchegger F Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):943-51. PubMed ID: 15824926 [TBL] [Abstract][Full Text] [Related]
6. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407 [TBL] [Abstract][Full Text] [Related]
7. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Boucek JA; Turner JH Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965 [TBL] [Abstract][Full Text] [Related]
8. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Koch W; Radau PE; Münzing W; Tatsch K Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):495-502. PubMed ID: 16435116 [TBL] [Abstract][Full Text] [Related]
9. Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer. Kobayashi M; Wakabayashi H; Kayano D; Konishi T; Kojima H; Yoneyama H; Okuda K; Tsushima H; Onoguchi M; Kawai K; Kinuya S Ann Nucl Med; 2014 Jul; 28(6):551-8. PubMed ID: 24710758 [TBL] [Abstract][Full Text] [Related]
10. Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab. Wahl RL; Horner TJ; Lin TS; Kaminski MS J Nucl Med; 2015 Nov; 56(11):1800-3. PubMed ID: 26338897 [TBL] [Abstract][Full Text] [Related]
11. Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. Rajendran JG; Gopal AK; Fisher DR; Durack LD; Gooley TA; Press OW J Nucl Med; 2008 May; 49(5):837-44. PubMed ID: 18413376 [TBL] [Abstract][Full Text] [Related]
12. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. Conti PS; White C; Pieslor P; Molina A; Aussie J; Foster P J Nucl Med; 2005 Nov; 46(11):1812-8. PubMed ID: 16269594 [TBL] [Abstract][Full Text] [Related]
13. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of novel whole-body high-resolution rodent SPECT (Linoview) based on direct acquisition of linogram projections. Walrand S; Jamar F; de Jong M; Pauwels S J Nucl Med; 2005 Nov; 46(11):1872-80. PubMed ID: 16269602 [TBL] [Abstract][Full Text] [Related]